SecBot SecBot
8-K ·Filed Nov 9, 2026

OCUL

OCULAR THERAPEUTIX, INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed7d 17h ago SEC0001104659-26-124159
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Board changes are routine and carry no immediate trading signal. Monitor for any future 8-K or proxy filing that might indicate a shift in strategic direction or governance, but no action warranted from this filing alone.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$6.85
T+0 close · Nov 9, 2026 · via day close
Latest settled
−12.26%
T+5 · $6.01
Vs SPY
−10.57%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $6.85entry
  2. T+1 · 7d ago −3.50%α −3.14% · $6.61
  3. T+5 · 18h ago −12.26%α −10.57% · $6.01
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocular Therapeutix elected Riad Sherif, M.D. to its board effective November 6, 2026, and received notice that director Seung Suh Hong, Ph.D. will resign effective December 31, 2026. Dr. Hong's resignation is stated as not due to any disagreement with the board or management. This is a routine board composition change with no material financial impact.

Key Facts

  • Riad Sherif, M.D. elected to the board as a Class I member, effective November 6, 2026
  • Dr. Sherif is CEO of Oculis Holding AG and has prior experience at Novartis, Alcon, and Sanofi
  • Dr. Sherif received an option for 88,000 shares at $6.60/share and an RSU award for 28,000 shares, both vesting annually over three years
  • Seung Suh Hong, Ph.D. notified the company of his resignation from the board, effective December 31, 2026
  • Dr. Hong's resignation is not the result of any disagreement with the board or management

Financial Impact

Standard non-employee director compensation: option for 88,000 shares and RSU for 28,000 shares, aggregate value approximately $765,600 based on $6.60 closing price

dilution

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-124159
Document: 0001104659-26-124159-index-headers.html0001104659-26-124159
Document: 0001104659-26-124159-index.html0001104659-26-124159
Document: 0001104659-26-124159.txt0001104659-26-124159

Track record

20 reports on OCUL

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
  2. Nov 9, 20267d ago 8-K Neutral 2/10 Viewing Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
  3. Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
  4. Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
  6. Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
  7. Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
  8. Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
  9. Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
  10. Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 8h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026